In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage […]
Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations […]
FreeMind is pleased to support the upcoming Life Sciences Summit! Where: New York City, NY When: November 1-2, 2017 The Life Sciences Summit is an early-stage investor and business development conference for emerging companies and academic innovators. The objective of the meeting is to connect emerging companies with early-stage investors, business development professionals, and medical […]
Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical. In this webinar, we discuss key CNS/PNS related funding opportunities, with […]
Sep 07, 2017 NEW YORK (GenomeWeb) – The US Senate’s appropriations committee today approved a funding bill that would increase the National Institutes of Health’s fiscal 2018 budget by $2 billion to $36.1 billion. The bill — which was cleared by the Senate Labor, Health and Human Services, and Education Appropriations Subcommittee yesterday — was approved by […]
In order to maximize your funding potential, all sources of funding must be considered, including the less traditional ones. The NIH’s R21 mechanism aims to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas the R01 mechanism is more suitable for longer programs of up to […]
FreeMind is a proud supporter of the upcoming Inv€$tival Showcase Where: London, UK When: November 14, 2017 Showcasing innovative investable Biotech, Medtech and Digital Health investment and partnering opportunities. Biotech and Money connects corporates to capital, and the Inv€$tival Showcase is our most direct way of showcasing the latest investable private and public life science opportunities […]